The DeLLphi-304 trial shows tarlatamab significantly improves survival with a manageable adverse-event profile over chemotherapy, establishing a new standard of care for patients with small cell lung cancer (SCLC) after platinum-based chemotherapy. Read More ›

A randomized, phase 2 study found atezolizumab maintenance after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC) did not improve survival outcomes and caused additional toxicities. Read More ›

The IMforte study showed clinically meaningful improvements in progression-free survival and overall survival with lurbinectedin plus atezolizumab compared with atezolizumab alone in patients with extensive-stage small cell lung cancer. Read More ›

ZG006 demonstrated promising efficacy and a tolerable safety profile in patients with advanced small cell lung cancer, supporting further evaluation in the ongoing phase 2 study. Read More ›